Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

SAGE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)

10/01/2020 | 04:21pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain


On September 30, 2020, the Board of Directors (the "Board") of Sage Therapeutics, Inc. (the "Company") elected Barry E. Greene to the Board. Mr. Greene was elected as a Class III director and will serve until the Company's annual meeting of stockholders in 2023 or until his successor is duly elected and qualified or his earlier resignation or removal.

Mr. Greene served as President of Alnylam Pharmaceuticals, Inc., a public biopharmaceutical company, from 2007 through September 2020, and served as its Chief Operating Officer from 2003 to September 2016. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., a public biopharmaceutical company, where he led the company's global strategy and execution for its oncology business. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company. Prior to Mediconsult.com, Mr. Greene's experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a pharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting, a consulting company, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene has served as a member of the boards of directors of Karyopharm Therapeutics, Inc., since 2013, and Acorda Therapeutics, Inc., since 2007. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University'sFuqua School of Business.

Mr. Greene does not have any family relationships with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Greene and any other person pursuant to which he was elected as a director of the Company.

In accordance with the Company's director compensation program, Mr. Greene is entitled to receive an annual cash retainer of $45,000 for service on the Board, which is payable quarterly in arrears, plus additional cash compensation if he is appointed to a Board committee. In addition, under the Company's director compensation program, in connection with his election to the Board, Mr. Greene was granted an option to purchase 20,000 shares of the Company's common stock at an exercise price per share equal to the closing price of the Company's common stock on the grant date. Such option vests in equal monthly installments during the 36 months following the grant date, subject to the director's continued service on the Board. Mr. Greene will enter into the Company's standard form of indemnification agreement for directors.

Item 8.01 Other Events.

On October 1, 2020, the Company issued a press release announcing the election of Mr. Greene to the Board. A copy of the press release is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  No.       Description

99.1          Press release issued by Sage Therapeutics, Inc. on October 1, 2020.

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)


© Edgar Online, source Glimpses

12/04SAGE THERAPEUTICS : to Present at BMO 2020 Growth and ESG Conference
12/03SAGE THERAPEUTICS : to Present at BMO 2020 Growth & ESG Conference
11/30BIOGEN : and Sage Therapeutics Announce Global Collaboration to Develop and Comm..
11/27BIOGEN : bets on depression drug in $1.5 billion deal with Sage Therapeutics
11/27SAGE THERAPEUTICS : Biogen bets on depression drug in $1.5 bln deal with Sage Th..
11/27BIOGEN : Sage Therapeutics Reach Global Collaboration for Potential Depression a..
11/27SAGE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregister..
11/27BIOGEN : and Sage Therapeutics Announce Global Collaboration to Develop and Comm..
11/05SAGE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
11/05SAGE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
More news